Funding for this research was provided by:
Anschutz Medical Campus, University of Colorado
Foundation for the National Institutes of Health (UL1 RR025780, UL1 RR025780)
Received: 22 July 2021
Accepted: 30 May 2022
First Online: 11 June 2022
: Scott: Research funding from Janssen Pharmaceuticals, Takeda Pharmaceuticals USA, and the Crohn’s and Colitis Foundation; and has received personal fees from PRIME Incorporated, Janssen Pharmaceuticals, Takeda Pharmaceuticals, and IBD REMEDY. Wani: Consultant Boston Scientific, Medtronic, Cernostics, Interpace. Edmundowicz: Consultant for and on the advisory board for Provation and Olympus. Patel: Freenome Inc (research support), Olympus America (research support), ERBE USA (honorarium). The other authors declare no competing interests.